Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Operating Leases (2019 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Operating Leases for 7 consecutive years, with $2.7 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Operating Leases fell 13.26% year-over-year to $2.7 million, compared with a TTM value of $2.7 million through Mar 2025, down 13.26%, and an annual FY2024 reading of $2.8 million, down 12.61% over the prior year.
  • Operating Leases was $2.7 million for Q1 2025 at Catalyst Pharmaceuticals, down from $2.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $4.0 million in Q3 2021 and bottomed at $2.7 million in Q1 2025.
  • Average Operating Leases over 5 years is $3.4 million, with a median of $3.4 million recorded in 2023.
  • The sharpest move saw Operating Leases fell 8.31% in 2022, then fell 13.26% in 2025.
  • Year by year, Operating Leases stood at $3.9 million in 2021, then dropped by 8.65% to $3.6 million in 2022, then fell by 10.37% to $3.2 million in 2023, then decreased by 12.61% to $2.8 million in 2024, then fell by 3.77% to $2.7 million in 2025.
  • Business Quant data shows Operating Leases for CPRX at $2.7 million in Q1 2025, $2.8 million in Q4 2024, and $3.1 million in Q1 2024.